CATHETER PRECISION INC (VTAK)
US74933X6094 - Common Stock
Taking everything into account, VTAK scores 1 out of 10 in our fundamental rating. VTAK was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of VTAK have multiple concerns. VTAK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year VTAK has reported negative net income.
VTAK had a negative operating cash flow in the past year.
In the past 5 years VTAK always reported negative net income.
VTAK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -36.14%, VTAK perfoms like the industry average, outperforming 42.25% of the companies in the same industry.
VTAK has a Return On Equity of -66.29%. This is comparable to the rest of the industry: VTAK outperforms 42.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROIC | N/A |
ROA(3y)-170.3%
ROA(5y)N/A
ROE(3y)-270.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VTAK has a Gross Margin of 92.20%. This is amongst the best in the industry. VTAK outperforms 99.47% of its industry peers.
VTAK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTAK does not have a ROIC to compare to the WACC, probably because it is not profitable.
VTAK has more shares outstanding than it did 1 year ago.
VTAK has a worse debt/assets ratio than last year.
2.2 Solvency
VTAK has an Altman-Z score of -16.39. This is a bad value and indicates that VTAK is not financially healthy and even has some risk of bankruptcy.
VTAK's Altman-Z score of -16.39 is on the low side compared to the rest of the industry. VTAK is outperformed by 85.56% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that VTAK is not too dependend on debt financing.
VTAK has a better Debt to Equity ratio (0.05) than 62.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -16.39 |
ROIC/WACCN/A
WACC14.8%
2.3 Liquidity
A Current Ratio of 0.12 indicates that VTAK may have some problems paying its short term obligations.
VTAK has a worse Current ratio (0.12) than 97.86% of its industry peers.
A Quick Ratio of 0.10 indicates that VTAK may have some problems paying its short term obligations.
VTAK has a Quick ratio of 0.10. This is amonst the worse of the industry: VTAK underperforms 97.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 |
3. Growth
3.1 Past
VTAK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.87%, which is quite impressive.
EPS 1Y (TTM)70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-27.82%
3.2 Future
Based on estimates for the next years, VTAK will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.87% on average per year.
Based on estimates for the next years, VTAK will show a quite strong growth in Revenue. The Revenue will grow by 13.26% on average per year.
EPS Next Y87.69%
EPS Next 2YN/A
EPS Next 3Y25.98%
EPS Next 5Y14.87%
Revenue Next Year-48.1%
Revenue Next 2YN/A
Revenue Next 3Y-25.92%
Revenue Next 5Y13.26%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
VTAK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTAK. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VTAK's earnings are expected to grow with 25.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3Y25.98%
5. Dividend
5.1 Amount
No dividends for VTAK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CATHETER PRECISION INC
NYSEARCA:VTAK (12/20/2024, 8:04:00 PM)
After market: 0.334 +0 (+1.21%)0.33
+0 (+0.92%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners2.53%
Inst Owner ChangeN/A
Ins Owners1.42%
Ins Owner Change0%
Market Cap2.64M
Analysts85.71
Price Target41.82 (12572.73%)
Short Float %0.5%
Short Ratio0.01
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-46.24%
Min EPS beat(2)-107.63%
Max EPS beat(2)15.16%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-61.59%
Min Revenue beat(2)-68.34%
Max Revenue beat(2)-54.84%
Revenue beat(4)0
Avg Revenue beat(4)-72.73%
Min Revenue beat(4)-86.93%
Max Revenue beat(4)-54.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.06 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-15805
EYN/A
EPS(NY)-1945.65
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.05
BVpS1.79
TBVpS-1.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.14% | ||
| ROE | -66.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 92.2% | ||
| FCFM | N/A |
ROA(3y)-170.3%
ROA(5y)N/A
ROE(3y)-270.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.12% | ||
| Cap/Sales | 19.72% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.12 | ||
| Quick Ratio | 0.1 | ||
| Altman-Z | -16.39 |
F-Score5
WACC14.8%
ROIC/WACCN/A
Cap/Depr(3y)8.21%
Cap/Depr(5y)N/A
Cap/Sales(3y)447.72%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.21%
EPS Next Y87.69%
EPS Next 2YN/A
EPS Next 3Y25.98%
EPS Next 5Y14.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-27.82%
Revenue Next Year-48.1%
Revenue Next 2YN/A
Revenue Next 3Y-25.92%
Revenue Next 5Y13.26%
EBIT growth 1Y55.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y73.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y73.25%
OCF growth 3YN/A
OCF growth 5YN/A